Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Nanchang University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Nanchang University
ClinicalTrials.gov Identifier:
NCT01152060
First received: June 28, 2010
Last updated: NA
Last verified: May 2010
History: No changes posted
  Purpose
Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Condition
Proteinuria
HBVe-antigen

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: an Open Parallel Clinical Trial in HBV-GN Patients

Further study details as provided by Nanchang University:

Biospecimen Retention:   Samples Without DNA
not available

Estimated Enrollment: 10
Study Start Date: January 2010
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
prednisone
prednisone and anti-virus

Detailed Description:
lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
HBV-MN patients with heavy proteinuria in adults; HBsAg or HBeAg positive; HBV-DNA negative
Criteria

Inclusion Criteria:

  • Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

Exclusion Criteria:

  • Primary MN patients, HBV-DNA positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01152060

Sponsors and Collaborators
Nanchang University
Investigators
Study Director: Gaosi XU, MD & PhD second affiliated hospital to nanchang university
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: ethics committee of Nanchang University, second affiliated hospital
ClinicalTrials.gov Identifier: NCT01152060     History of Changes
Study First Received: June 28, 2010
Last Updated: June 28, 2010
Health Authority: China: Food and Drug Administration

Keywords provided by Nanchang University:
remission of proteinuria
HBVe-antigen

Additional relevant MeSH terms:
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Prednisone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 24, 2016